TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Palo Alto (17 mi)Overseen byFarshid Dayyani, MD, PhD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: University of California, Irvine
No Placebo Group
Trial Summary
What is the purpose of this trial?This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: TAS-102 and IrinotecanExperimental Treatment2 Interventions
Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
Irinotecan is already approved in United States, European Union, Japan, Canada for the following indications:
🇺🇸 Approved in United States as Camptosar for:
- Colorectal cancer
🇪🇺 Approved in European Union as Irinotecan for:
- Colorectal cancer
🇯🇵 Approved in Japan as Topotecin for:
- Colorectal cancer
- Small cell lung cancer
🇨🇦 Approved in Canada as Irinotecan for:
- Colorectal cancer
Find a clinic near you
Research locations nearbySelect from list below to view details:
Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, CA
UC Davis Comprehensive Cancer CenterSacramento, CA
Loading ...
Who is running the clinical trial?
University of California, IrvineLead Sponsor
Taiho Pharmaceutical Co., Ltd.Industry Sponsor